^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Estrogen receptor agonist

    Related drugs:
    7d
    Ovulation Incidence in Oral Contraceptive Users (clinicaltrials.gov)
    P3, N=58, Suspended, University of Southern California | Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    8d
    IDEAL: Improving Diagnostics in Cervical Dysplasia (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, University of Aarhus | Not yet recruiting --> Recruiting | Trial completion date: Mar 2025 --> Jul 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
    Enrollment open • Trial completion date • Trial primary completion date
    12d
    Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial (clinicaltrials.gov)
    P2, N=58, Recruiting, University of Utah | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    20d
    VITAL-E: Silicone Gel Vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Stratpharma AG | Trial completion date: Jun 2024 --> Nov 2025 | Trial primary completion date: Jun 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • Head-to-Head
    26d
    Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation (clinicaltrials.gov)
    P4, N=60, Not yet recruiting, University of Southern California
    New P4 trial
    1m
    CLEAR-3: Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach (clinicaltrials.gov)
    P4, N=90, Completed, University of Illinois at Chicago | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Aug 2024 | Trial primary completion date: Dec 2024 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    1m
    Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women (clinicaltrials.gov)
    P4, N=86, Completed, Mahidol University | Active, not recruiting --> Completed
    Trial completion
    1m
    Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate (clinicaltrials.gov)
    P2, N=0, Withdrawn, Weill Medical College of Cornell University | N=40 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    2ms
    Estrogen Hormone Products (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Maryland, Baltimore | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    2ms
    Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling. (PubMed, Curr Oncol)
    Numerous studies have highlighted the efficacy of BZA (monotherapy or combined with other chemotherapy drugs) in impeding progression across multiple cancers. In this review, we mainly focus on the anticancer activity of BZA and the underlying anticancer mechanism through inhibition of the IL-6/GP130 pathway, aiming to provide valuable insights for the design and execution of further research and the potential repositioning of BZA in oncological clinical trials.
    Review • Journal
    |
    IL6 (Interleukin 6)
    2ms
    The G-Protein-Coupled Estrogen Receptor Agonist G-1 Mediates Antitumor Effects by Activating Apoptosis Pathways and Regulating Migration and Invasion in Cervical Cancer Cells. (PubMed, Cancers (Basel))
    GPER is a promising prognostic marker due to its ability to activate apoptosis and inhibit proliferation without promoting migration/invasion in CC cells. G-1 could potentially be a tool in the treatment of this neoplasia.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • DKK1 (dickkopf WNT signaling pathway inhibitor 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • VIM (Vimentin) • FOSL1 (FOS Like 1) • IL1B (Interleukin 1, beta) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    DKK1 overexpression • VIM expression
    2ms
    Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1. (PubMed, J Clin Med)
    IGF-1 levels decreased by 41% with ADT+E4 versus an increase of 10% with ADT+placebo (p < 0.0001). The almost complete suppression of the tumor stimulator FSH using ADT plus E4 observed in all individual patients in this study, along with the augmented suppression of IGF-1 versus an increase by ADT only, may be clinically relevant and suggest the enhanced anti-cancer treatment efficacy of E4 in addition to the previously reported additional suppression of total and free T and PSA.
    Journal
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Donesta (estetrol)
    3ms
    Efficacy of Combined Pharmacotherapy Versus Solifenacin with Vaginal Estrogen Cream for Women with Detrusor Overactivity (clinicaltrials.gov)
    P4, N=100, Recruiting, Mackay Memorial Hospital | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    mirabegron
    3ms
    A prospective, randomised controlled study of retention enema-assisted treatment of uterine adhesions with Chinese medicine (ChiCTR2400087131)
    P=N/A, N=290, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital
    New trial
    |
    estradiol valerate
    3ms
    A multicenter, randomized, double-blind, placebo-controlled, parallel-design phase III clinical study to evaluate the efficacy and safety of oral relugoli tablets in the treatment of heavy menstrual bleeding associated with uterine fibroids (ChiCTR2400088811)
    P3, N=120, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    New P3 trial
    |
    medroxyprogesterone • estradiol valerate
    3ms
    Study on the effects of intestinal bacteria transplantation on glycolipid metabolism and body composition in patients with polycystic ovary syndrome (ChiCTR2400087346)
    P1, N=84, Recruiting, Beijing Obstetrics and Gynecology Hospital, Capital Medical University; Beijing Obstetrics and Gynecology Hospital, Capital Medical University
    New P1 trial
    4ms
    The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial (clinicaltrials.gov)
    P3, N=110, Recruiting, Main Line Health | Not yet recruiting --> Recruiting
    Enrollment open • Surgery
    |
    Orgovyx (relugolix)
    4ms
    Engineered mitochondria exert potent antitumor immunity as a cancer vaccine platform. (PubMed, Cell Mol Immunol)
    Engineered OVA- and TRP2-containing mitochondria (OVA-MITO and TRP2-MITO) were extracted and evaluated as potential cancer vaccines...The results demonstrated that engineered mitochondria are natively well-orchestrated carriers full of immune stimulants for antigen delivery, which could preferably target local dendritic cells and exert strong adaptive cellular immunity. This proof-of-concept study established a universal platform for vaccine construction with engineered mitochondria bearing alterable antigens for cancers as well as other diseases.
    Journal
    |
    TLR2 (Toll Like Receptor 2)
    4ms
    CLEAR-3: Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach (clinicaltrials.gov)
    P4, N=90, Active, not recruiting, University of Illinois at Chicago | Recruiting --> Active, not recruiting
    Enrollment closed
    4ms
    Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome (clinicaltrials.gov)
    P4, N=152, Recruiting, Walter Reed National Military Medical Center | Trial completion date: Jan 2024 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    mirabegron
    4ms
    Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, Mayo Clinic | Enrolling by invitation --> Active, not recruiting | N=38 --> 5
    Enrollment closed • Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor)
    4ms
    Estrogen and Fear in PTSD (clinicaltrials.gov)
    P3, N=80, Recruiting, NYU Langone Health | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    4ms
    Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome (clinicaltrials.gov)
    P4, N=50, Recruiting, Aarhus University Hospital
    New P4 trial
    |
    Divigel (estradiol)
    5ms
    Unilateral vs Bilateral Laparoscopic Ovarian Drilling In Clomiphene Citrate Resistant Cases of Polycystic Ovarian Syndrome (clinicaltrials.gov)
    P=N/A, N=130, Completed, Tanta University
    New trial
    5ms
    Syzygium malaccense leaves methanol extract modulate some biochemical and inflammatory markers and prostate histology of testosterone-estradiol valerate induced benign prostatic hyperplasia in rats. (PubMed, Avicenna J Phytomed)
    SMLE showed strong in vitro antioxidant activity which corroborated its in vivo antioxidant activity. The study showed that S. malaccense could be useful in the management of BPH.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
    |
    estradiol valerate
    5ms
    Microtubule depolymerization induces ferroptosis in neuroblastoma cells. (PubMed, IUBMB Life)
    Estramustine (EM), a clinically successful hormone-refractory anti-prostate cancer drug, exhibited potent anti-proliferative activity, depolymerized microtubules, blocked cells at mitosis, and induced cell death in different cancer cells...Ferroptosis inhibitors (deferoxamine mesylate and liproxstatin-1) abrogated the cytotoxic effects of EM, further confirming ferroptosis induction. Vinblastine and nocodazole also increased LIP and induced lipid peroxidation in neuroblastoma cells. This study provides evidence for the coupling of microtubule integrity to ferroptosis. The results also suggest that microtubule-depolymerizing agents may be considered for developing pro-ferroptosis chemotherapeutics.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    vinblastine • Emcyt (estramustine) • liproxstatin-1
    5ms
    Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (clinicaltrials.gov)
    P3, N=478, Completed, AbbVie | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    5ms
    The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial (clinicaltrials.gov)
    P3, N=110, Not yet recruiting, Main Line Health | Trial completion date: Apr 2027 --> Aug 2026
    Trial completion date • Surgery
    |
    Orgovyx (relugolix)
    5ms
    Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women: A Randomized Controlled Study (clinicaltrials.gov)
    P4, N=86, Active, not recruiting, Mahidol University
    New P4 trial
    5ms
    The effect of PPOS+Clomiphene Citrate protocal for IVF-ET therapy in patients with low basal LH (ChiCTR1800014440)
    P=N/A, N=115, Recruiting, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University Scho | N=230 --> 115
    Enrollment change
    6ms
    Comparison Between Two Ovulation Induction Therapies and LOD on Clinical Outcomes in CC-Resistant PCOS Women (clinicaltrials.gov)
    P3, N=183, Completed, Cairo University
    New P3 trial
    |
    letrozole
    6ms
    Impact of Estradiol on Endothelial Function in Peri-Menopausal Women (clinicaltrials.gov)
    P4, N=80, Recruiting, University of Delaware | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    6ms
    The elucidation of species-specific receptor pharmacology: a case study using subtype selective para- and meta-carborane estrogen receptor agonists. (PubMed, J Pharmacol Exp Ther)
    These findings shed light on the intricacies of using preclinical species in drug development to predict human pharmacology. The report also provides insights for the refinement and optimization of carborane analogs as potential therapeutic agents for estrogen-related disease states.
    Journal
    |
    ER (Estrogen receptor)
    6ms
    Comparative Bioavailability Study of Ethinyl Estradiol/Etonogestrel Vaginal Ring (clinicaltrials.gov)
    P1, N=36, Completed, Evestra Inc. | Recruiting --> Completed
    Trial completion
    6ms
    A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant (clinicaltrials.gov)
    P1, N=40, Recruiting, Novo Nordisk A/S | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Far Eastern Memorial Hospital | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    6ms
    A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Novo Nordisk A/S
    New P1 trial
    7ms
    Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=38, Enrolling by invitation, Mayo Clinic | Trial completion date: Apr 2024 --> Jul 2026 | Trial primary completion date: Apr 2024 --> Jul 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor)
    7ms
    The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial (clinicaltrials.gov)
    P3, N=110, Not yet recruiting, Main Line Health
    New P3 trial • Surgery
    |
    Orgovyx (relugolix)
    7ms
    eTAPE: Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, McGill University Health Centre/Research Institute of the McGill University Health Centre | N=40 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    7ms
    A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012) (clinicaltrials.gov)
    P2, N=666, Completed, Organon and Co | Phase classification: P2b --> P2
    Phase classification
    7ms
    Zoely vs. Zoloft in Premenstrual Dysphoric Disorder (ACTRN12623000496617)
    P2, N=160, Recruiting, Monash University | Not yet recruiting --> Recruiting
    Enrollment open